id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0529-0011,FDA,FDA-2012-D-0529,"Recommended Statement for Over-the-Counter Aspirin-Containing Drug
Products Labeled With Cardiovascular-Related Imagery; Guidance for
Industry; Availability",Notice,Notice of Availability,2017-11-07T05:00:00Z,2017,11,2017-11-07T05:00:00Z,,2017-11-07T15:31:28Z,2017-24192,0,0,0900006482c53e92
FDA-2012-D-0529-0012,FDA,FDA-2012-D-0529,Recommended Statement for Over-the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery Guidance for Industry,Other,Guidance,2017-11-07T05:00:00Z,2017,11,2017-11-07T05:00:00Z,,2024-11-07T01:10:16Z,,1,0,0900006482c548f3
FDA-2012-D-0529-0007,FDA,FDA-2012-D-0529,Recommended Statement for Over-the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery,Other,Guidance,2017-01-11T05:00:00Z,2017,1,2017-01-11T05:00:00Z,,2024-11-12T06:18:07Z,,1,0,090000648245ba09
FDA-2012-D-0529-0006,FDA,FDA-2012-D-0529,"Recommended Statement for Over-the-Counter Aspirin-Containing Drug
Products Labeled With Cardiovascular Related Imagery; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-01-11T05:00:00Z,2017,1,2017-01-11T05:00:00Z,2017-03-14T03:59:59Z,2017-03-14T01:02:02Z,2017-00374,0,0,090000648245aff6